IMV Inc IMVIQ

RE:RE:RE:RE:RE:Updated Results from Phase 2 SPiReL Study Evaluating IMV’s D

[antisense]

CORRECTION***  With all due respect you are getting your trials confused.

Decide1 trial is for ovarian cancer and Spiral is for DBCL.

Totally different enrollement numbers and results.  We were talking about the Spiral trial which

"At the time of data cut-off for the abstract on June 27, 2019, 23 subjects have been screened and 12 have been enrolled"

but "The final conference poster presentation will include additional data collected between the abstract submission and the presentation itself"

and based on the trial outline: "Participants will undergo "re-staging" to assess the status of their disease at approximately study day 70 (if there is evidence of Grade 2 or greater injection site reaction or ulceration evident on study day 49) or routinely at approximately study day 91, and again at end of study or study withdrawal for all participants.

So looks like after 91 days for any patient newly enrolled new results will be available.  We could be in for some good new substantial results betwene June 27 (only 12 enrolled and submitted)  and  Dec 8th.

 

Hideaway wrote:  Based on June 1st release, the enrollment target is 28 patients. In that NR they indicated 19 had been enrolled to date, with 7 evaluable.

In the Aug.8th financial results release they indicated the following:"We have enrolled 16 additional patients in the expanded monotherapy arm of the DeCidE1 trial. IMV expects to provide the top-line clinical results from this study before the end of 2019."

This would bring total to 23 enrolled as of Aug 8th
Not sure how long it takes to start evaluating patients,but, if Qwerty's calculations hold, it would appear as only one additional patient was added to the 7 evaluated in the June 1st release.
GLTA

[/quote]